董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven Felsher | 男 | Independent Director | 77 | 1.25万美元 | 0.85 | 2026-10-23 |
| Paul DiPerna | 男 | Chairman of the Board,Chief Financial Officer,President and Treasurer | 67 | 66.29万美元 | 8.51 | 2026-10-23 |
| Ellen O' Connor Vos | 女 | Director | 70 | 3.60万美元 | 0.06 | 2026-10-23 |
| Morgan C. Frank | 男 | Director | 54 | 1.38万美元 | 0.69 | 2026-10-23 |
| Carmen Volkart | 女 | Independent Director | 65 | 0.59万美元 | 0.09 | 2026-10-23 |
| Philip Sheibley | 男 | Independent Director | 67 | 4.10万美元 | 0.32 | 2026-10-23 |
| James Besser | 男 | Director and Chief Executive Officer | 50 | 4.70万美元 | 1.41 | 2026-10-23 |
| Jeffrey Goldberg | 男 | Independent Director | 60 | 3.03万美元 | 未持股 | 2026-10-23 |
| Duane DeSisto | 男 | Independent Director | 71 | 3.47万美元 | 0.93 | 2026-10-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul DiPerna | 男 | Chairman of the Board,Chief Financial Officer,President and Treasurer | 67 | 66.29万美元 | 8.51 | 2026-10-23 |
| James Besser | 男 | Director and Chief Executive Officer | 50 | 4.70万美元 | 1.41 | 2026-10-23 |
| Kevin Schmid | 男 | Chief Operating Officer | 67 | 37.57万美元 | 未持股 | 2026-10-23 |
董事简历
中英对照 | 中文 | 英文- Steven Felsher
-
Steven Felsher于2018年7月14日加入董事会。Felsher先生是一位经验丰富的高管，负责公共和私人公司管理的财务，行政，治理和其他方面。Felsher先生在Grey Global Group Inc.（一家全球营销服务公司）度过了他职业生涯的大部分时间，他从1979年到2007年在该公司担任高级管理人员，最近的职位是担任副董事长兼首席财务官。2011年1月以来，他一直担任Quadrangle Group LLC（私人投资公司，专注于信息和通信技术部门）的高级顾问，在那里他曾担任其投资和估值委员会的成员。此外，Felsher先生是Armory Square Ventures的投资合伙人，该公司是一家风险投资基金，专注于早期科技公司的投资。Felsher先生曾担任众多公司的董事会成员。此外，Felsher先生是布鲁克林音乐学院（Brooklyn Academy of Music）的长期受托人，也是BAM Endowment Trust（监督BAM&8217；s Endowment）的受托人。Felsher先生也是纽约医学院（New York Academy of Medicine）的研究员、受托人和财务主管，以及肌肉萎缩症协会（Muscular Dystrophy Association）的董事。
Steven Felsher was appointed to Modular Medical, Inc.'s board of directors in November 2021. Mr. Felsher is an experienced executive with respect to finance, administration, governance and other aspects of public and private company management. He served as a member of the board of directors of Signal Hill Acquisition Corp., a special purpose acquisition company, from March 2021 to February 2023. From August 2018 to July 2020, he served as a member of the board of directors of Sito Mobile, Inc., a publicly traded company that provided customized, data driven solutions for brands spanning all forms of media. From January 2011 to June 2019, Mr. Felsher was a senior advisor at Quadrangle Group LLC, a private investment firm focused on the information and communications technology sectors. Currently retired, he spent a substantial portion of his career with Grey Global Group Inc., a global marketing services company, where he served as a senior executive from 1979 until 2007, most recently as vice chairman and chief financial officer. He holds a BA in classical Greek from Dickinson College and a J.D. from Yale University School of Law. - Steven Felsher于2018年7月14日加入董事会。Felsher先生是一位经验丰富的高管，负责公共和私人公司管理的财务，行政，治理和其他方面。Felsher先生在Grey Global Group Inc.（一家全球营销服务公司）度过了他职业生涯的大部分时间，他从1979年到2007年在该公司担任高级管理人员，最近的职位是担任副董事长兼首席财务官。2011年1月以来，他一直担任Quadrangle Group LLC（私人投资公司，专注于信息和通信技术部门）的高级顾问，在那里他曾担任其投资和估值委员会的成员。此外，Felsher先生是Armory Square Ventures的投资合伙人，该公司是一家风险投资基金，专注于早期科技公司的投资。Felsher先生曾担任众多公司的董事会成员。此外，Felsher先生是布鲁克林音乐学院（Brooklyn Academy of Music）的长期受托人，也是BAM Endowment Trust（监督BAM&8217；s Endowment）的受托人。Felsher先生也是纽约医学院（New York Academy of Medicine）的研究员、受托人和财务主管，以及肌肉萎缩症协会（Muscular Dystrophy Association）的董事。
- Steven Felsher was appointed to Modular Medical, Inc.'s board of directors in November 2021. Mr. Felsher is an experienced executive with respect to finance, administration, governance and other aspects of public and private company management. He served as a member of the board of directors of Signal Hill Acquisition Corp., a special purpose acquisition company, from March 2021 to February 2023. From August 2018 to July 2020, he served as a member of the board of directors of Sito Mobile, Inc., a publicly traded company that provided customized, data driven solutions for brands spanning all forms of media. From January 2011 to June 2019, Mr. Felsher was a senior advisor at Quadrangle Group LLC, a private investment firm focused on the information and communications technology sectors. Currently retired, he spent a substantial portion of his career with Grey Global Group Inc., a global marketing services company, where he served as a senior executive from 1979 until 2007, most recently as vice chairman and chief financial officer. He holds a BA in classical Greek from Dickinson College and a J.D. from Yale University School of Law.
- Paul DiPerna
-
Paul Diperna自2017年7月我们收购Quasuras，Inc.以来一直是我们的董事长，首席财务官，总裁兼财务主管。从2017年7月到2021年8月，他还担任我们的首席执行官。2015年，他创立了Quasuras，Inc.，这是一家开发胰岛素泵产品的早期医疗设备公司，在被我们收购之前，他担任其首席执行官兼董事长。在此之前，DiPerna先生创立了Fuel Source Partners，LLC，以孵化早期医疗设备产品并积累技术人才。我们目前的泵产品就是此类拟议产品之一，并于2015年分拆给了Quasuras。从2012年到2015年，他担任一家私人公司的共同发明人，该公司拥有用于血液传播感染控制的医疗设备的产权，该设备被3M Corporation收购。2003年，Diperna先生创立了Tandem Diabetes Care, Inc.“；Tandem”；，并担任多个职位，包括担任董事、首席执行官和首席技术官，主要负责Tandem最初的胰岛素泵的设计概念和开发。此前，他曾担任Baxter 医疗保健Corporation（“；Baxter”；）的执行和管理职务，在那里他曾负责识别糖尿病行业的协同机会。因此，DiPerna先生在糖尿病行业发展了大量的专业知识和知识，并领导了Baxter收购三家胰岛素泵制造商的尝试。此前，他曾担任自动化测试设备和血液分离科学行业的机械设计工程职务。Diperna先生在医疗设备和微流体技术方面拥有70项专利，并获得了FDA的众多产品许可。他还在之前的公司中成功退出了多家公司。Diperna先生获得了东北大学的工程管理硕士学位和马萨诸塞大学的机械工程学士学位，并在医疗设备行业工作了35年以上。
Paul DiPerna has been Modular Medical, Inc.'s chairman, chief financial officer, president and treasurer since Modular Medical, Inc. acquired Quasuras, Inc. ("Quasuras") in July 2017. He also served as Modular Medical, Inc.'s chief executive officer from July 2017 until August 2021, and as Modular Medical, Inc.'s Secretary from July 2017 to October 2021. In 2015, he founded Quasuras, an early stage medical device company developing an insulin pump product, and, until its acquisition by Modular Medical, Inc., he served as its chief executive officer and chairman. Prior to that, Mr. DiPerna founded Fuel Source Partners, LLC to incubate early stage medical device products and accumulate technical talent. Modular Medical, Inc.'s current pump product was one of such proposed products and was spun out to Quasuras in 2015. From 2012 to 2015, he served as a co inventor at a private company with property rights in a medical device used for blood borne infection control called the Curos Cap, which was acquired by 3M Corporation. In 2003, Mr. DiPerna founded Tandem Diabetes Care, Inc. ("Tandem") and held various positions, including as director, chief executive officer and chief technology officer and was primarily responsible for the design concept and development of Tandem's initial insulin pump. Prior to that, he held executive and management positions at Baxter Healthcare Corporation ("Baxter") where he was tasked with identifying synergistic opportunities in the diabetes industry. As a result, Mr. DiPerna developed substantial expertise and knowledge in the diabetes industry and led attempts by Baxter to acquire three insulin pump manufacturers. Previously, he held mechanical design engineering positions in the automated test equipment and blood separation sciences industries. Mr. DiPerna holds approximately 70 patents in medical device and microfluidic technology and has achieved numerous product clearances with the FDA. He has also achieved multiple successful exits with previous companies. Mr. DiPerna received a Masters in Engineering Management from Northeastern University and a B.S. in Mechanical Engineering from the University of Massachusetts and has spent over 35 years in the medical device industry. - Paul Diperna自2017年7月我们收购Quasuras，Inc.以来一直是我们的董事长，首席财务官，总裁兼财务主管。从2017年7月到2021年8月，他还担任我们的首席执行官。2015年，他创立了Quasuras，Inc.，这是一家开发胰岛素泵产品的早期医疗设备公司，在被我们收购之前，他担任其首席执行官兼董事长。在此之前，DiPerna先生创立了Fuel Source Partners，LLC，以孵化早期医疗设备产品并积累技术人才。我们目前的泵产品就是此类拟议产品之一，并于2015年分拆给了Quasuras。从2012年到2015年，他担任一家私人公司的共同发明人，该公司拥有用于血液传播感染控制的医疗设备的产权，该设备被3M Corporation收购。2003年，Diperna先生创立了Tandem Diabetes Care, Inc.“；Tandem”；，并担任多个职位，包括担任董事、首席执行官和首席技术官，主要负责Tandem最初的胰岛素泵的设计概念和开发。此前，他曾担任Baxter 医疗保健Corporation（“；Baxter”；）的执行和管理职务，在那里他曾负责识别糖尿病行业的协同机会。因此，DiPerna先生在糖尿病行业发展了大量的专业知识和知识，并领导了Baxter收购三家胰岛素泵制造商的尝试。此前，他曾担任自动化测试设备和血液分离科学行业的机械设计工程职务。Diperna先生在医疗设备和微流体技术方面拥有70项专利，并获得了FDA的众多产品许可。他还在之前的公司中成功退出了多家公司。Diperna先生获得了东北大学的工程管理硕士学位和马萨诸塞大学的机械工程学士学位，并在医疗设备行业工作了35年以上。
- Paul DiPerna has been Modular Medical, Inc.'s chairman, chief financial officer, president and treasurer since Modular Medical, Inc. acquired Quasuras, Inc. ("Quasuras") in July 2017. He also served as Modular Medical, Inc.'s chief executive officer from July 2017 until August 2021, and as Modular Medical, Inc.'s Secretary from July 2017 to October 2021. In 2015, he founded Quasuras, an early stage medical device company developing an insulin pump product, and, until its acquisition by Modular Medical, Inc., he served as its chief executive officer and chairman. Prior to that, Mr. DiPerna founded Fuel Source Partners, LLC to incubate early stage medical device products and accumulate technical talent. Modular Medical, Inc.'s current pump product was one of such proposed products and was spun out to Quasuras in 2015. From 2012 to 2015, he served as a co inventor at a private company with property rights in a medical device used for blood borne infection control called the Curos Cap, which was acquired by 3M Corporation. In 2003, Mr. DiPerna founded Tandem Diabetes Care, Inc. ("Tandem") and held various positions, including as director, chief executive officer and chief technology officer and was primarily responsible for the design concept and development of Tandem's initial insulin pump. Prior to that, he held executive and management positions at Baxter Healthcare Corporation ("Baxter") where he was tasked with identifying synergistic opportunities in the diabetes industry. As a result, Mr. DiPerna developed substantial expertise and knowledge in the diabetes industry and led attempts by Baxter to acquire three insulin pump manufacturers. Previously, he held mechanical design engineering positions in the automated test equipment and blood separation sciences industries. Mr. DiPerna holds approximately 70 patents in medical device and microfluidic technology and has achieved numerous product clearances with the FDA. He has also achieved multiple successful exits with previous companies. Mr. DiPerna received a Masters in Engineering Management from Northeastern University and a B.S. in Mechanical Engineering from the University of Massachusetts and has spent over 35 years in the medical device industry.
- Ellen O' Connor Vos
-
Ellen O’Connor Vos于2021年5月被任命为我们的董事会成员，自2021年8月起担任我们的首席执行官。Vos女士自2020年11月以来一直担任Voshealth LLC的成员。在此之前，她于2017年10月至2020年11月担任肌肉萎缩症协会的总裁兼首席执行官。此前，Vos女士曾于1996年至2017年担任GHG|GreyHealth Group的首席执行官，她一直是利用数字功能改善公共健康的倡导者。Vos女士还担任Optimizerx Corporation（一家公开上市的数字健康公司）和JED Foundation（一家领先的非营利组织，致力于保护大学生的情绪健康）的董事会成员，并且是MMRF（一家开拓性的癌症研究基金会）的创始董事会成员。Vos女士拥有阿尔弗雷德大学的护理学士学位。
Ellen O' Connor Vos has served as a member of the Board of Directors since May 2021 and served as chief executive officer from August 2021 until February 23, 2022. Ms. Vos has served as a member of VosHealth LLC, a healthcare consultancy firm, since November 2020. Prior to that, she served as the president and chief executive officer of the Mcular Dystrophy Association from October 2017 to November 2020. Previoly, Ms. Vos had been chief executive officer of ghg | greyhealth group from 1996 to 2017, and she has been a champion of ing digital capabilities to improve the public health. Ms. Vos also serves on the board of OptimizeRX Corporation, a publicly traded digital health company, and the Jed Foundation, a leading nonprofit dedicated to protecting the emotional health of college students, and was a founding board member of MMRF, a pioneering cancer research foundation. Ms. Vos holds a B.S. in nursing from Alfred University. - Ellen O’Connor Vos于2021年5月被任命为我们的董事会成员，自2021年8月起担任我们的首席执行官。Vos女士自2020年11月以来一直担任Voshealth LLC的成员。在此之前，她于2017年10月至2020年11月担任肌肉萎缩症协会的总裁兼首席执行官。此前，Vos女士曾于1996年至2017年担任GHG|GreyHealth Group的首席执行官，她一直是利用数字功能改善公共健康的倡导者。Vos女士还担任Optimizerx Corporation（一家公开上市的数字健康公司）和JED Foundation（一家领先的非营利组织，致力于保护大学生的情绪健康）的董事会成员，并且是MMRF（一家开拓性的癌症研究基金会）的创始董事会成员。Vos女士拥有阿尔弗雷德大学的护理学士学位。
- Ellen O' Connor Vos has served as a member of the Board of Directors since May 2021 and served as chief executive officer from August 2021 until February 23, 2022. Ms. Vos has served as a member of VosHealth LLC, a healthcare consultancy firm, since November 2020. Prior to that, she served as the president and chief executive officer of the Mcular Dystrophy Association from October 2017 to November 2020. Previoly, Ms. Vos had been chief executive officer of ghg | greyhealth group from 1996 to 2017, and she has been a champion of ing digital capabilities to improve the public health. Ms. Vos also serves on the board of OptimizeRX Corporation, a publicly traded digital health company, and the Jed Foundation, a leading nonprofit dedicated to protecting the emotional health of college students, and was a founding board member of MMRF, a pioneering cancer research foundation. Ms. Vos holds a B.S. in nursing from Alfred University.
- Morgan C. Frank
-
Morgan C.Frank于2017年4月被任命为我们的董事会成员。Frank先生自2002年5月以来在Manchester Explorer，LP工作，在此之前，他是First Principles Group的Founder兼董事总经理，这是一家精品咨询公司和主要投资者，专门从事公司重组，重启，知识产权评估和打捞以及分拆。在此之前，Frank先生在Hollis Capital担任了大约5年的分析师和投资组合经理，该公司是一家总部位于旧金山的对冲基金，Frank先生在Paine Webber的一家独立私人客户集团工作，专门从事主要研究，以开发投资理念，尤其是为机构客户提供的卖空理念。在加入Paine Webber之前，Frank先生是Eastern Vanguard的货币交易员。Frank先生拥有布朗大学经济学和政治学学士学位。
Morgan C. Frank was appointed to Modular Medical, Inc.'s board of directors in April 2017. In August 2022, he was appointed as chairman of the board of directors of SANUWAVE Health, Inc., a publicly traded provider of wound care products, and, in May 2023, was appointed its chief executive officer. Mr. Frank served as portfolio manager at Manchester since May 2002, and, prior to such time, he was a founder and managing director at First Principles Group, a boutique consultancy and principal investor specializing in corporate restructuring, restarts, intellectual property assessment and salvage, and spin outs. Prior to such time, Mr. Frank spent approximately five years as an analyst and portfolio manager at Hollis Capital, a San Francisco based hedge fund and prior thereto, Mr. Frank worked for an independent private client group at Paine Webber specializing in primary research to develop investment ideas (particularly short sale ideas) for institutional clients. Prior to his employment at Paine Webber, Mr. Frank was a currency trader for Eastern Vanguard. Mr. Frank holds a BA in Economics and in Political Science from Brown University. - Morgan C.Frank于2017年4月被任命为我们的董事会成员。Frank先生自2002年5月以来在Manchester Explorer，LP工作，在此之前，他是First Principles Group的Founder兼董事总经理，这是一家精品咨询公司和主要投资者，专门从事公司重组，重启，知识产权评估和打捞以及分拆。在此之前，Frank先生在Hollis Capital担任了大约5年的分析师和投资组合经理，该公司是一家总部位于旧金山的对冲基金，Frank先生在Paine Webber的一家独立私人客户集团工作，专门从事主要研究，以开发投资理念，尤其是为机构客户提供的卖空理念。在加入Paine Webber之前，Frank先生是Eastern Vanguard的货币交易员。Frank先生拥有布朗大学经济学和政治学学士学位。
- Morgan C. Frank was appointed to Modular Medical, Inc.'s board of directors in April 2017. In August 2022, he was appointed as chairman of the board of directors of SANUWAVE Health, Inc., a publicly traded provider of wound care products, and, in May 2023, was appointed its chief executive officer. Mr. Frank served as portfolio manager at Manchester since May 2002, and, prior to such time, he was a founder and managing director at First Principles Group, a boutique consultancy and principal investor specializing in corporate restructuring, restarts, intellectual property assessment and salvage, and spin outs. Prior to such time, Mr. Frank spent approximately five years as an analyst and portfolio manager at Hollis Capital, a San Francisco based hedge fund and prior thereto, Mr. Frank worked for an independent private client group at Paine Webber specializing in primary research to develop investment ideas (particularly short sale ideas) for institutional clients. Prior to his employment at Paine Webber, Mr. Frank was a currency trader for Eastern Vanguard. Mr. Frank holds a BA in Economics and in Political Science from Brown University.
- Carmen Volkart
-
Carmen Volkart于2019年12月被任命为我们的董事会成员。自2018年10月以来，她一直担任NatureWorks LLC的首席财务官，该公司是一家先进材料公司，提供可再生来源的聚合物投资组合。从2012年10月至2018年7月，Volkart女士担任NXThera，Inc.的首席财务官，并在部分时间内担任商业化高级副总裁，该公司是一家医疗设备公司，率先将对流射频热疗法应用于治疗持续期疾病。她曾担任Tornier N.V.公司的全球首席财务官（从2010年到2012年），也曾担任Spine Wave公司的首席运营和财务官、公司秘书、合规官和财务主管（从2006年到2010年）。2006年之前，Volkart女士在American Medical，Inc.，美敦力公司和Honeywell，Inc.担任多个执行和财务职位。她拥有北达科他州大学的会计学士学位和明尼苏达大学的工商管理硕士学位，专注于战略管理。
Carmen Volkart was appointed to Modular Medical, Inc.'s board of directors in December 2019. Since January 2023, she has served as a member of the board of directors of Tactile Systems Technology, Inc. (Tactile Medical), a Nasdaq listed, medical technology company developing and marketing at home therapies for people suffering from underserved, chronic conditions. Ms. Volkart served as chief financial officer of Natureworks LLC, an advanced materials company offering a portfolio of renewably sourced polymers, from October 2018 to September 2023. She served as a member of the board of directors, including as a member of the audit committee of Antares Pharma, Inc., a Nasdaq listed, specialty pharmaceutical company, from October 2021 to May 2022, when it was acquired by another Nasdaq listed company. From October 2012 to July 2018, Ms. Volkart served as chief financial officer and, for a portion of that time, as senior vice president of commercialization for NxThera, Inc., a medical device company pioneering the application of convective radiofrequency thermotherapy to treat endourological conditions. She served as global chief financial officer of Tornier N.V. from 2010 to 2012, and was chief operating and financial officer, corporate secretary, compliance officer and treasurer of Spine Wave, Inc. from 2006 to 2010. Prior to 2006, Ms. Volkart held various executive and financial positions at American Medical Systems, Inc., Medtronic, Inc. and Honeywell, Inc. She holds a B.S. in accounting from the University of North Dakota and an MBA with a concentration in strategic management from the University of Minnesota. - Carmen Volkart于2019年12月被任命为我们的董事会成员。自2018年10月以来，她一直担任NatureWorks LLC的首席财务官，该公司是一家先进材料公司，提供可再生来源的聚合物投资组合。从2012年10月至2018年7月，Volkart女士担任NXThera，Inc.的首席财务官，并在部分时间内担任商业化高级副总裁，该公司是一家医疗设备公司，率先将对流射频热疗法应用于治疗持续期疾病。她曾担任Tornier N.V.公司的全球首席财务官（从2010年到2012年），也曾担任Spine Wave公司的首席运营和财务官、公司秘书、合规官和财务主管（从2006年到2010年）。2006年之前，Volkart女士在American Medical，Inc.，美敦力公司和Honeywell，Inc.担任多个执行和财务职位。她拥有北达科他州大学的会计学士学位和明尼苏达大学的工商管理硕士学位，专注于战略管理。
- Carmen Volkart was appointed to Modular Medical, Inc.'s board of directors in December 2019. Since January 2023, she has served as a member of the board of directors of Tactile Systems Technology, Inc. (Tactile Medical), a Nasdaq listed, medical technology company developing and marketing at home therapies for people suffering from underserved, chronic conditions. Ms. Volkart served as chief financial officer of Natureworks LLC, an advanced materials company offering a portfolio of renewably sourced polymers, from October 2018 to September 2023. She served as a member of the board of directors, including as a member of the audit committee of Antares Pharma, Inc., a Nasdaq listed, specialty pharmaceutical company, from October 2021 to May 2022, when it was acquired by another Nasdaq listed company. From October 2012 to July 2018, Ms. Volkart served as chief financial officer and, for a portion of that time, as senior vice president of commercialization for NxThera, Inc., a medical device company pioneering the application of convective radiofrequency thermotherapy to treat endourological conditions. She served as global chief financial officer of Tornier N.V. from 2010 to 2012, and was chief operating and financial officer, corporate secretary, compliance officer and treasurer of Spine Wave, Inc. from 2006 to 2010. Prior to 2006, Ms. Volkart held various executive and financial positions at American Medical Systems, Inc., Medtronic, Inc. and Honeywell, Inc. She holds a B.S. in accounting from the University of North Dakota and an MBA with a concentration in strategic management from the University of Minnesota.
- Philip Sheibley
-
Philip Sheibley于2021年11月被任命为我们的董事会成员。Sheibley先生是一位经验丰富的高管和风险投资家。2011年以来，他担任Alumni Investment Partners（私人股本公司）的负责人。从1981年到2010年，他曾担任Accenture公司的管理和技术顾问，在那里他专注于生命科学领域，担任多种领导职务，包括生命科学的北美行业董事，以及管理咨询的全球负责人。Sheibley先生拥有利哈伊大学工业和系统工程学士学位，辅修商业。
Philip Sheibley was appointed to Modular Medical, Inc.'s board of directors in November 2021. Mr. Sheibley is an experienced executive and venture capitalist. Since 2011, he has served as a principal at Alumni Investment Partners, a private equity firm. From 1981 to 2010, Mr. Sheibley served as a management and technology consultant with Accenture, where he focused on the life sciences area, holding a variety of leadership positions, including North American industry director for life sciences and global lead for management consulting. Mr. Sheibley holds a B.S. in industrial and systems engineering with a business minor from Lehigh University. - Philip Sheibley于2021年11月被任命为我们的董事会成员。Sheibley先生是一位经验丰富的高管和风险投资家。2011年以来，他担任Alumni Investment Partners（私人股本公司）的负责人。从1981年到2010年，他曾担任Accenture公司的管理和技术顾问，在那里他专注于生命科学领域，担任多种领导职务，包括生命科学的北美行业董事，以及管理咨询的全球负责人。Sheibley先生拥有利哈伊大学工业和系统工程学士学位，辅修商业。
- Philip Sheibley was appointed to Modular Medical, Inc.'s board of directors in November 2021. Mr. Sheibley is an experienced executive and venture capitalist. Since 2011, he has served as a principal at Alumni Investment Partners, a private equity firm. From 1981 to 2010, Mr. Sheibley served as a management and technology consultant with Accenture, where he focused on the life sciences area, holding a variety of leadership positions, including North American industry director for life sciences and global lead for management consulting. Mr. Sheibley holds a B.S. in industrial and systems engineering with a business minor from Lehigh University.
- James Besser
-
James Besser自2022年2月23日起担任Modular Medical首席执行官，在另类投资、战略咨询、公司战略和公司治理方面拥有超过25年的经验。自1999年以来，他一直是投资管理公司曼彻斯特管理公司（曼彻斯特）的管理成员。Besser先生目前也是River Stone Biotech公司的董事，该公司是一家处于发展阶段的专业生物加工公司。他拥有布朗大学的历史学学士学位。我们认为，Besser先生有资格担任Modular Medical董事会成员，是因为他在对上市公司（其中某些公司处于发展阶段）进行财务分析方面拥有丰富的经验，包括此类上市公司的管理团队、产品（包括处于发展阶段的产品）、此类产品的潜在市场以及可能影响此类实体的产品成功的可能性和时间以及市场渗透率的其他因素以及他的筹资活动。
James Besser has served as Modular Medical, Inc.'s chief executive officer since February 2022 and combines over 25 years of experience in alternative investments, strategic advisory, corporate strategy and corporate governance. Since 1999, he has been a managing member at Manchester Management Company, LLC ("Manchester"), an investment management firm. Mr. Besser is also currently a director of River Stone Biotech, a development stage specialty bioprocessing company. He holds a B.A. in history from Brown University. - James Besser自2022年2月23日起担任Modular Medical首席执行官，在另类投资、战略咨询、公司战略和公司治理方面拥有超过25年的经验。自1999年以来，他一直是投资管理公司曼彻斯特管理公司（曼彻斯特）的管理成员。Besser先生目前也是River Stone Biotech公司的董事，该公司是一家处于发展阶段的专业生物加工公司。他拥有布朗大学的历史学学士学位。我们认为，Besser先生有资格担任Modular Medical董事会成员，是因为他在对上市公司（其中某些公司处于发展阶段）进行财务分析方面拥有丰富的经验，包括此类上市公司的管理团队、产品（包括处于发展阶段的产品）、此类产品的潜在市场以及可能影响此类实体的产品成功的可能性和时间以及市场渗透率的其他因素以及他的筹资活动。
- James Besser has served as Modular Medical, Inc.'s chief executive officer since February 2022 and combines over 25 years of experience in alternative investments, strategic advisory, corporate strategy and corporate governance. Since 1999, he has been a managing member at Manchester Management Company, LLC ("Manchester"), an investment management firm. Mr. Besser is also currently a director of River Stone Biotech, a development stage specialty bioprocessing company. He holds a B.A. in history from Brown University.
- Jeffrey Goldberg
-
杰弗里·戈德堡于2025年5月被任命为董事会成员。他是一位经验丰富的高管，目前和过去曾担任多家公司的董事会成员和主席。自2023年12月起，Goldberg先生担任ATI Physical Therapy，Inc.的董事会成员，该公司是一家在全国范围内上市的物理治疗服务提供商。他目前还担任以下公司的董事会成员：Eating Recovery Centers/Pathlight、Lannett Company，Inc.和Banza。戈德堡先生获得了加州大学洛杉矶分校法学院的法学博士学位和哈佛学院哲学专业的A.B.学位。
Jeffrey Goldberg was appointed to Modular Medical, Inc.'s board of directors in May 2025. He is an experienced executive who currently and in the past has served as a member and chair of the board of directors of multiple companies. In May 2026, Mr. Goldberg was appointed to the board of directors of Beasley Broadcast Group Inc., a Nasdaq listed multiplatform media company providing advertising and digital marketing solutions across the United States. Since December 2023, he has served as a member of the board of directors of ATI Physical Therapy, Inc., a publicly traded nationwide provider of physical therapy services. Mr. Goldberg also currently serves as a member of the board of directors of the following companies: Eating Recovery Centers/Pathlight, Lannett Company, Inc. and Banza. He earned his J.D. from UCLA School of Law and his A.B. with a concentration in Philosophy from Harvard College. - 杰弗里·戈德堡于2025年5月被任命为董事会成员。他是一位经验丰富的高管，目前和过去曾担任多家公司的董事会成员和主席。自2023年12月起，Goldberg先生担任ATI Physical Therapy，Inc.的董事会成员，该公司是一家在全国范围内上市的物理治疗服务提供商。他目前还担任以下公司的董事会成员：Eating Recovery Centers/Pathlight、Lannett Company，Inc.和Banza。戈德堡先生获得了加州大学洛杉矶分校法学院的法学博士学位和哈佛学院哲学专业的A.B.学位。
- Jeffrey Goldberg was appointed to Modular Medical, Inc.'s board of directors in May 2025. He is an experienced executive who currently and in the past has served as a member and chair of the board of directors of multiple companies. In May 2026, Mr. Goldberg was appointed to the board of directors of Beasley Broadcast Group Inc., a Nasdaq listed multiplatform media company providing advertising and digital marketing solutions across the United States. Since December 2023, he has served as a member of the board of directors of ATI Physical Therapy, Inc., a publicly traded nationwide provider of physical therapy services. Mr. Goldberg also currently serves as a member of the board of directors of the following companies: Eating Recovery Centers/Pathlight, Lannett Company, Inc. and Banza. He earned his J.D. from UCLA School of Law and his A.B. with a concentration in Philosophy from Harvard College.
- Duane DeSisto
-
Duane DeSisto，2003年起，他担任Unilife Corporation总裁、首席执行官和董事。2002至2003年，他担任Unilife Corporation总裁、首席财务官和代理首席执行官。2001至2002年，他担任Unilife Corporation首席财务官和会计长。1999至2001年，他在一家纸浆造纸业商业解决方案供应商PaperExchange.com, Inc.担任多职，包括总裁、首席执行官和首席财务官。1995至1999年，他担任配件批发商FGX International Holdings Limited前身为 AAI-Foster Grant, Inc.的首席财务官，负责所有会计、信息技术和人力资源部门。1986至1995年，他担任ZOLL Medical Corporation的首席财务官，ZOLL Medical Corporation是一家医疗设备公司，专门从事非侵入性复苏设备和相关软件解决方案。他在普维敦斯学院（Providence College）获得理学士学位，在布莱恩特学院（Bryant College）获得工商管理学硕士学位。
Duane DeSisto was appointed to Modular Medical, Inc.'s board of directors in July 2023. He has over 45 years of progressive management experience and over 25 years of experience in the medical device industry as a member of senior management and as a board member at multiple public companies. Currently retired, he previously served as the chief executive officer of Insulet Corporation ("Insulet"), manufacturer of the world's first patch insulin pump, from 2003 to 2014. Prior to 2001, he held executive positions with Paper Exchange, an e business solution for the pulp and paper industry, AAI Foster Grant, a sunglass and eyeglass provider to point of purchase retail, and Zoll Medical, a defibrillator manufacturer. He has an undergraduate degree from Providence College and a masters of business administration degree from Bryant University. - Duane DeSisto，2003年起，他担任Unilife Corporation总裁、首席执行官和董事。2002至2003年，他担任Unilife Corporation总裁、首席财务官和代理首席执行官。2001至2002年，他担任Unilife Corporation首席财务官和会计长。1999至2001年，他在一家纸浆造纸业商业解决方案供应商PaperExchange.com, Inc.担任多职，包括总裁、首席执行官和首席财务官。1995至1999年，他担任配件批发商FGX International Holdings Limited前身为 AAI-Foster Grant, Inc.的首席财务官，负责所有会计、信息技术和人力资源部门。1986至1995年，他担任ZOLL Medical Corporation的首席财务官，ZOLL Medical Corporation是一家医疗设备公司，专门从事非侵入性复苏设备和相关软件解决方案。他在普维敦斯学院（Providence College）获得理学士学位，在布莱恩特学院（Bryant College）获得工商管理学硕士学位。
- Duane DeSisto was appointed to Modular Medical, Inc.'s board of directors in July 2023. He has over 45 years of progressive management experience and over 25 years of experience in the medical device industry as a member of senior management and as a board member at multiple public companies. Currently retired, he previously served as the chief executive officer of Insulet Corporation ("Insulet"), manufacturer of the world's first patch insulin pump, from 2003 to 2014. Prior to 2001, he held executive positions with Paper Exchange, an e business solution for the pulp and paper industry, AAI Foster Grant, a sunglass and eyeglass provider to point of purchase retail, and Zoll Medical, a defibrillator manufacturer. He has an undergraduate degree from Providence College and a masters of business administration degree from Bryant University.
高管简历
中英对照 | 中文 | 英文- Paul DiPerna
Paul Diperna自2017年7月我们收购Quasuras，Inc.以来一直是我们的董事长，首席财务官，总裁兼财务主管。从2017年7月到2021年8月，他还担任我们的首席执行官。2015年，他创立了Quasuras，Inc.，这是一家开发胰岛素泵产品的早期医疗设备公司，在被我们收购之前，他担任其首席执行官兼董事长。在此之前，DiPerna先生创立了Fuel Source Partners，LLC，以孵化早期医疗设备产品并积累技术人才。我们目前的泵产品就是此类拟议产品之一，并于2015年分拆给了Quasuras。从2012年到2015年，他担任一家私人公司的共同发明人，该公司拥有用于血液传播感染控制的医疗设备的产权，该设备被3M Corporation收购。2003年，Diperna先生创立了Tandem Diabetes Care, Inc.“；Tandem”；，并担任多个职位，包括担任董事、首席执行官和首席技术官，主要负责Tandem最初的胰岛素泵的设计概念和开发。此前，他曾担任Baxter 医疗保健Corporation（“；Baxter”；）的执行和管理职务，在那里他曾负责识别糖尿病行业的协同机会。因此，DiPerna先生在糖尿病行业发展了大量的专业知识和知识，并领导了Baxter收购三家胰岛素泵制造商的尝试。此前，他曾担任自动化测试设备和血液分离科学行业的机械设计工程职务。Diperna先生在医疗设备和微流体技术方面拥有70项专利，并获得了FDA的众多产品许可。他还在之前的公司中成功退出了多家公司。Diperna先生获得了东北大学的工程管理硕士学位和马萨诸塞大学的机械工程学士学位，并在医疗设备行业工作了35年以上。
Paul DiPerna has been Modular Medical, Inc.'s chairman, chief financial officer, president and treasurer since Modular Medical, Inc. acquired Quasuras, Inc. ("Quasuras") in July 2017. He also served as Modular Medical, Inc.'s chief executive officer from July 2017 until August 2021, and as Modular Medical, Inc.'s Secretary from July 2017 to October 2021. In 2015, he founded Quasuras, an early stage medical device company developing an insulin pump product, and, until its acquisition by Modular Medical, Inc., he served as its chief executive officer and chairman. Prior to that, Mr. DiPerna founded Fuel Source Partners, LLC to incubate early stage medical device products and accumulate technical talent. Modular Medical, Inc.'s current pump product was one of such proposed products and was spun out to Quasuras in 2015. From 2012 to 2015, he served as a co inventor at a private company with property rights in a medical device used for blood borne infection control called the Curos Cap, which was acquired by 3M Corporation. In 2003, Mr. DiPerna founded Tandem Diabetes Care, Inc. ("Tandem") and held various positions, including as director, chief executive officer and chief technology officer and was primarily responsible for the design concept and development of Tandem's initial insulin pump. Prior to that, he held executive and management positions at Baxter Healthcare Corporation ("Baxter") where he was tasked with identifying synergistic opportunities in the diabetes industry. As a result, Mr. DiPerna developed substantial expertise and knowledge in the diabetes industry and led attempts by Baxter to acquire three insulin pump manufacturers. Previously, he held mechanical design engineering positions in the automated test equipment and blood separation sciences industries. Mr. DiPerna holds approximately 70 patents in medical device and microfluidic technology and has achieved numerous product clearances with the FDA. He has also achieved multiple successful exits with previous companies. Mr. DiPerna received a Masters in Engineering Management from Northeastern University and a B.S. in Mechanical Engineering from the University of Massachusetts and has spent over 35 years in the medical device industry.- Paul Diperna自2017年7月我们收购Quasuras，Inc.以来一直是我们的董事长，首席财务官，总裁兼财务主管。从2017年7月到2021年8月，他还担任我们的首席执行官。2015年，他创立了Quasuras，Inc.，这是一家开发胰岛素泵产品的早期医疗设备公司，在被我们收购之前，他担任其首席执行官兼董事长。在此之前，DiPerna先生创立了Fuel Source Partners，LLC，以孵化早期医疗设备产品并积累技术人才。我们目前的泵产品就是此类拟议产品之一，并于2015年分拆给了Quasuras。从2012年到2015年，他担任一家私人公司的共同发明人，该公司拥有用于血液传播感染控制的医疗设备的产权，该设备被3M Corporation收购。2003年，Diperna先生创立了Tandem Diabetes Care, Inc.“；Tandem”；，并担任多个职位，包括担任董事、首席执行官和首席技术官，主要负责Tandem最初的胰岛素泵的设计概念和开发。此前，他曾担任Baxter 医疗保健Corporation（“；Baxter”；）的执行和管理职务，在那里他曾负责识别糖尿病行业的协同机会。因此，DiPerna先生在糖尿病行业发展了大量的专业知识和知识，并领导了Baxter收购三家胰岛素泵制造商的尝试。此前，他曾担任自动化测试设备和血液分离科学行业的机械设计工程职务。Diperna先生在医疗设备和微流体技术方面拥有70项专利，并获得了FDA的众多产品许可。他还在之前的公司中成功退出了多家公司。Diperna先生获得了东北大学的工程管理硕士学位和马萨诸塞大学的机械工程学士学位，并在医疗设备行业工作了35年以上。
- Paul DiPerna has been Modular Medical, Inc.'s chairman, chief financial officer, president and treasurer since Modular Medical, Inc. acquired Quasuras, Inc. ("Quasuras") in July 2017. He also served as Modular Medical, Inc.'s chief executive officer from July 2017 until August 2021, and as Modular Medical, Inc.'s Secretary from July 2017 to October 2021. In 2015, he founded Quasuras, an early stage medical device company developing an insulin pump product, and, until its acquisition by Modular Medical, Inc., he served as its chief executive officer and chairman. Prior to that, Mr. DiPerna founded Fuel Source Partners, LLC to incubate early stage medical device products and accumulate technical talent. Modular Medical, Inc.'s current pump product was one of such proposed products and was spun out to Quasuras in 2015. From 2012 to 2015, he served as a co inventor at a private company with property rights in a medical device used for blood borne infection control called the Curos Cap, which was acquired by 3M Corporation. In 2003, Mr. DiPerna founded Tandem Diabetes Care, Inc. ("Tandem") and held various positions, including as director, chief executive officer and chief technology officer and was primarily responsible for the design concept and development of Tandem's initial insulin pump. Prior to that, he held executive and management positions at Baxter Healthcare Corporation ("Baxter") where he was tasked with identifying synergistic opportunities in the diabetes industry. As a result, Mr. DiPerna developed substantial expertise and knowledge in the diabetes industry and led attempts by Baxter to acquire three insulin pump manufacturers. Previously, he held mechanical design engineering positions in the automated test equipment and blood separation sciences industries. Mr. DiPerna holds approximately 70 patents in medical device and microfluidic technology and has achieved numerous product clearances with the FDA. He has also achieved multiple successful exits with previous companies. Mr. DiPerna received a Masters in Engineering Management from Northeastern University and a B.S. in Mechanical Engineering from the University of Massachusetts and has spent over 35 years in the medical device industry.
- James Besser
James Besser自2022年2月23日起担任Modular Medical首席执行官，在另类投资、战略咨询、公司战略和公司治理方面拥有超过25年的经验。自1999年以来，他一直是投资管理公司曼彻斯特管理公司（曼彻斯特）的管理成员。Besser先生目前也是River Stone Biotech公司的董事，该公司是一家处于发展阶段的专业生物加工公司。他拥有布朗大学的历史学学士学位。我们认为，Besser先生有资格担任Modular Medical董事会成员，是因为他在对上市公司（其中某些公司处于发展阶段）进行财务分析方面拥有丰富的经验，包括此类上市公司的管理团队、产品（包括处于发展阶段的产品）、此类产品的潜在市场以及可能影响此类实体的产品成功的可能性和时间以及市场渗透率的其他因素以及他的筹资活动。
James Besser has served as Modular Medical, Inc.'s chief executive officer since February 2022 and combines over 25 years of experience in alternative investments, strategic advisory, corporate strategy and corporate governance. Since 1999, he has been a managing member at Manchester Management Company, LLC ("Manchester"), an investment management firm. Mr. Besser is also currently a director of River Stone Biotech, a development stage specialty bioprocessing company. He holds a B.A. in history from Brown University.- James Besser自2022年2月23日起担任Modular Medical首席执行官，在另类投资、战略咨询、公司战略和公司治理方面拥有超过25年的经验。自1999年以来，他一直是投资管理公司曼彻斯特管理公司（曼彻斯特）的管理成员。Besser先生目前也是River Stone Biotech公司的董事，该公司是一家处于发展阶段的专业生物加工公司。他拥有布朗大学的历史学学士学位。我们认为，Besser先生有资格担任Modular Medical董事会成员，是因为他在对上市公司（其中某些公司处于发展阶段）进行财务分析方面拥有丰富的经验，包括此类上市公司的管理团队、产品（包括处于发展阶段的产品）、此类产品的潜在市场以及可能影响此类实体的产品成功的可能性和时间以及市场渗透率的其他因素以及他的筹资活动。
- James Besser has served as Modular Medical, Inc.'s chief executive officer since February 2022 and combines over 25 years of experience in alternative investments, strategic advisory, corporate strategy and corporate governance. Since 1999, he has been a managing member at Manchester Management Company, LLC ("Manchester"), an investment management firm. Mr. Besser is also currently a director of River Stone Biotech, a development stage specialty bioprocessing company. He holds a B.A. in history from Brown University.
- Kevin Schmid
Kevin Schmid在医疗器械高级管理层和全球大规模制造业务方面拥有超过19年的经验。他自2022年3月起担任公司顾问。自2018年以来，Schmid先生一直担任Eitan Medical的董事会成员，Eitan Medical是一家位于以色列的联网输液和可穿戴药物输送解决方案供应商。2018年至2021年6月，他担任一次性注射笔剂量监测和报告技术公司Common Sensing，Inc.的首席执行官和董事会成员。2016年至2017年，Schmid先生担任Stevanato Group给药系统副总裁，该公司是一家为制药行业提供创新包装和给药解决方案的供应商。从2003年到2015年，施密德先生是Insulet Corporation公司的制造、运营和给药系统副总裁。他拥有克拉克森大学的BSME学位和圣心大学的MBA学位。
Kevin Schmid has served as Modular Medical, Inc.'s chief operating officer since July 2022. He has over 19 years of experience in medical device senior management and high volume global manufacturing operations. He served as a consultant to the Company from March 2022 until his hire date. Mr. Schmid served as a member of the board of directors of Eitan Medical, an Israel based provider of connected infusion and wearable drug delivery solutions, from 2018 to 2022. From 2018 through June 2021, he served as the chief executive officer and a board member of Common Sensing, Inc., a disposable injector pen dose monitoring and reporting technology company. From 2016 to 2017, Mr. Schmid was vice president of drug delivery systems for the Stevanato Group, a provider of innovative packaging and drug delivery solutions for the pharmaceutical industry. From 2003 to 2015, Mr. Schmid was vice president of manufacturing, operations, and drug delivery systems for Insulet Corporation. He has a BSME degree from Clarkson University and an MBA from Sacred Heart University.- Kevin Schmid在医疗器械高级管理层和全球大规模制造业务方面拥有超过19年的经验。他自2022年3月起担任公司顾问。自2018年以来，Schmid先生一直担任Eitan Medical的董事会成员，Eitan Medical是一家位于以色列的联网输液和可穿戴药物输送解决方案供应商。2018年至2021年6月，他担任一次性注射笔剂量监测和报告技术公司Common Sensing，Inc.的首席执行官和董事会成员。2016年至2017年，Schmid先生担任Stevanato Group给药系统副总裁，该公司是一家为制药行业提供创新包装和给药解决方案的供应商。从2003年到2015年，施密德先生是Insulet Corporation公司的制造、运营和给药系统副总裁。他拥有克拉克森大学的BSME学位和圣心大学的MBA学位。
- Kevin Schmid has served as Modular Medical, Inc.'s chief operating officer since July 2022. He has over 19 years of experience in medical device senior management and high volume global manufacturing operations. He served as a consultant to the Company from March 2022 until his hire date. Mr. Schmid served as a member of the board of directors of Eitan Medical, an Israel based provider of connected infusion and wearable drug delivery solutions, from 2018 to 2022. From 2018 through June 2021, he served as the chief executive officer and a board member of Common Sensing, Inc., a disposable injector pen dose monitoring and reporting technology company. From 2016 to 2017, Mr. Schmid was vice president of drug delivery systems for the Stevanato Group, a provider of innovative packaging and drug delivery solutions for the pharmaceutical industry. From 2003 to 2015, Mr. Schmid was vice president of manufacturing, operations, and drug delivery systems for Insulet Corporation. He has a BSME degree from Clarkson University and an MBA from Sacred Heart University.